Saxenda® Frenzy: Opinions of an Endocrine and Metabolism Specialist / 임상당뇨병
Journal of Korean Diabetes
;
: 63-66, 2019.
Article
in Korean
| WPRIM
| ID: wpr-761483
ABSTRACT
Globally, the problem of obesity is increasing, and the prevalence of obesity in Korea is also rising rapidly. Obesity is a risk factor for cardiometabolic diseases including type 2 diabetes mellitus, hypertension, cardiovascular disease, and some types of cancer. Therefore, prevention of various metabolic diseases or symptom relief through effective treatment of obesity is a very important problem. According to the obesity guidelines of the Obesity Society of Korea in 2018, obesity medication is recommended for patients with a body mass index (BMI) of 30 kg/m² or more or a BMI of 27 kg/m² or more, and one or more obesity accompanying diseases (type 2 diabetes, hypertension, dyslipidemia). In this case, it is recommended that the basic treatment for obesity (diet, exercise, and behavior therapy) should be performed in parallel with Saxenda® treatment. The glucagon-like peptide 1 analogue, Saxenda®, has been validated as a long-term effective and safe treatment for obesity, and is expected to be a promising drug for the treatment of obesity and the prevention of pre-diabetes in the future. However, in Korea, where non-standard obesity treatments are widely practiced, it is necessary to improve the health of obese patients by being treated with Saxenda® along with diet, exercise and behavior therapy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Specialization
/
Behavior Therapy
/
Cardiovascular Diseases
/
Body Mass Index
/
Prevalence
/
Risk Factors
/
Diabetes Mellitus
/
Diabetes Mellitus, Type 2
/
Diet
/
Glucagon-Like Peptide 1
Type of study:
Etiology study
/
Practice guideline
/
Prevalence study
/
Risk factors
Limits:
Humans
Country/Region as subject:
Asia
Language:
Korean
Journal:
Journal of Korean Diabetes
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS